SARS-CoV-2 mRNA Vaccines as Immunologic Adjuvants to Overcome Tumour Resistance to Immune Checkpoint Blockade

Immune checkpoint inhibitors (ICIs) have transformed oncologic care, yet their therapeutic efficacy remains limited in many patients due to tumour-intrinsic immune evasion and an immunosuppressive tumour microenvironment (TME) [1]. Recent evidence indicates that SARS-CoV-2 mRNA vaccines exert potent immunomodulatory effects beyond antiviral protection, acting as systemic primers of innate and adaptive immunity [2]. mRNA–lipid nanoparticle (LNP) formulations induce robust type I interferon signalling, dendritic-cell activation, and cytokine re-modelling, thereby reshaping the TME toward an immune-permissive state [3]. These immune-activating processes have been shown to enhance responsiveness to ICI therapy by promoting antitumor inflammation. In combined clinical and preclinical analyses, mRNA vaccination has been associated with increased tumour PD-L1 expression, expansion of effector CD8⁺ T cells, and enhanced activation of antigen-presenting cells (APCs) [4]. Collectively, these immune effects sensitize tumours to anti–PD-1/PD-L1 therapy [4]. Across large real-world oncology cohorts, patients who received COVID-19 mRNA vaccination exhibited improved survival following ICI treatment [4]. Notably, the strongest clinical benefit was observed when vaccination preceded ICI initiation [4]. Parallel murine studies confirmed that mRNA–LNP administration drives interferon-mediated tumour inflammation. These studies further demonstrated increased T-cell infiltration and synergistic enhancement of checkpoint-blockade efficacy in immunologically “cold” tumour models. These collective findings suggest that mRNA vaccines act as systemic immune adjuvants, establishing a primed immunologic baseline that increases tumour sensitivity to immune checkpoint blockade [2]. Despite this promise, heterogeneity in vaccination timing, tumour type, and baseline immune competence remains a major challenge for clinical integration [1]. Future research should prioritise the mechanistic dissection of mRNA-induced innate conditioning to optimise its use with ICIs [3]. Prospective evaluation is also needed to determine optimal sequencing strategies for vaccine–ICI combinations [4]. Additionally, mRNA-based adjuvant platforms may provide a foundation for next-generation immunotherapies [2]. In summary, SARS-CoV-2 mRNA vaccines represent a novel and clinically relevant strategy to overcome ICI resistance by reprogramming the tumour–immune interface [4]. This emerging paradigm offers new translational avenues for combination immunotherapy [1].